{"entity":{"id":"agennix","kind":"company","name":"Agennix","aka":["Agennix AG","Agennix Incorporated"],"tldr":"Agennix was a German-American biotech whose oral talactoferrin, a recombinant form of the milk protein lactoferrin, failed a phase 3 trial in non-small cell lung cancer.","summary":"Agennix, founded in 1993 with operations in Princeton, New Jersey and Munich, developed talactoferrin alfa, a recombinant human lactoferrin taken by mouth as an immunotherapy. The phase 3 FORTIS-M trial in previously treated non-small cell lung cancer did not improve survival, and the company ceased operations. Its trials remain on ClinicalTrials.gov under Agennix as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://agennix.com"},{"label":"ClinicalTrials.gov: trials led by Agennix AG","url":"https://clinicaltrials.gov/search?lead=Agennix%20AG"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q30283567"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Princeton, NJ","country":"US","companyType":"biotech","website":"http://agennix.com","founded":1993,"stage":"defunct","investors":[],"funding":[]},"route":"/companies/agennix/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"term":[{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/"},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/"}]}}